Publications by authors named "I S Nam-Goong"
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).
Endocrinol Metab (Seoul)
October 2024
Article Synopsis
- Atherogenic dyslipidemia is a condition linked to type 2 diabetes that can cause serious heart problems.
- Statins are usually the main medicine given to help lower cholesterol, but researchers want to see if combining them with other drugs like ezetimibe and fibrates can work better.
- In a study with nearly 4,000 people, scientists will compare the effects of adding ezetimibe and fibrates to statins versus just increasing the dose of statins alone, looking for improvements over four years.
Article Synopsis
- * Conducted as a double-blind, phase III trial, it involved 185 adults with specific HbA1c and LDL-C levels, and after 16 weeks of treatment, the combination group showed significant improvements in both HbA1c and LDL-C compared to those only on either drug.
- * The results indicated that using metformin with atorvastatin led to better management of blood sugar and cholesterol levels, suggesting this combination could be beneficial for patients struggling to control their conditions with lifestyle changes alone. *
Purpose: Self-management of diabetes is a significant challenge. This study aimed to assess diabetes self-care activities and barriers among Korean young adults with diabetes mellitus.
Materials And Methods: This study recruited 209 Korean adults with diabetes, with an onset age of 20-39 years, from four university hospitals.
Backgruound: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are currently used to treat patients with diabetes. Previous studies have demonstrated that treatment with SGLT-2 inhibitors is accompanied by altered metabolic phenotypes. However, it has not been investigated whether the hypothalamic circuit participates in the development of the compensatory metabolic phenotypes triggered by the treatment with SGLT-2 inhibitors.
View Article and Find Full Text PDF